|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2011-4-18
|
|
pubmed:abstractText |
In patients with epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma, treatment with erlotinib or gefitinib is associated with a 75% radiographic response rate and progression-free survival of approximately 12 months. The most common mechanism of acquired resistance to erlotinib is development of a secondary mutation in EGFR, suggesting that these tumors continue to depend on EGFR signaling. We hypothesized that combined EGFR blockade would overcome acquired resistance to erlotinib in patients with lung adenocarcinoma. To evaluate the toxicity and efficacy of cetuximab and erlotinib in patients with acquired resistance to erlotinib, we conducted this phase I/II clinical trial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AzzoliChristopher GCG,
pubmed-author:GinsbergMichelle SMS,
pubmed-author:JanjigianYelena YYY,
pubmed-author:KrisMark GMG,
pubmed-author:KrugLee MLM,
pubmed-author:MillerVincent AVA,
pubmed-author:PereiraLeanne KLK,
pubmed-author:PietanzaM CatherineMC,
pubmed-author:RielyGregory JGJ,
pubmed-author:RizviNaiyer ANA,
pubmed-author:WillettM AMA
|
|
pubmed:copyrightInfo |
©2011 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2521-7
|
|
pubmed:meshHeading |
pubmed-meshheading:21248303-Adenocarcinoma,
pubmed-meshheading:21248303-Aged,
pubmed-meshheading:21248303-Antibodies, Monoclonal,
pubmed-meshheading:21248303-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21248303-Dose-Response Relationship, Drug,
pubmed-meshheading:21248303-Drug Administration Schedule,
pubmed-meshheading:21248303-Drug Resistance, Neoplasm,
pubmed-meshheading:21248303-Exanthema,
pubmed-meshheading:21248303-Fatigue,
pubmed-meshheading:21248303-Female,
pubmed-meshheading:21248303-Humans,
pubmed-meshheading:21248303-Lung Neoplasms,
pubmed-meshheading:21248303-Male,
pubmed-meshheading:21248303-Middle Aged,
pubmed-meshheading:21248303-Quinazolines,
pubmed-meshheading:21248303-Receptor, Epidermal Growth Factor,
pubmed-meshheading:21248303-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
|
|
pubmed:affiliation |
Gastrointestinal and Thoracic Oncology Services, Division of Solid Tumor Oncology, Department of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
